Camblong Jurgi sold $45K of SOPH
Camblong Jurgi (Chief Executive Officer) sold 8,500 shares of SOPHiA GENETICS SA (SOPH) at $5.24 on 2026-06-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size, price ($5.2354/share), and that it occurred under a pre-arranged 10b5-1 plan; this may slightly affect sentiment but is unlikely to change fundamentals.
Market read
Traders may note the insider sale for sentiment/positioning, but the 10b5-1 structure makes it a low-conviction bearish catalyst.
What to watch
The filing does not indicate intent beyond the plan; without additional context (e.g., buy transactions, frequency, or changes in plan size), signal quality is limited.
Background
This is an SEC Form 4 insider transaction (open-market sale) by SOPHiA GENETICS CEO Camblong Jurgi.
Ticker impact
CEO Camblong Jurgi sold 8,500 SOPH shares for ~$44.5K on 2026-06-10 under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4; any reaction is likely muted.
The disclosure is an open-market sale by the CEO, but explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s view of near-term valuation or liquidity needs.
Key entities
- issuerSOPHiA GENETICS SA
Company whose shares were sold by its CEO under a 10b5-1 plan.
- insiderCamblong Jurgi
CEO and director who executed the open-market sale.
